RETRACTED: A new Er(III)-based MOF showing anti-colon cancer activity by inhibiting IL-6-STAT3 signaling pathway and reducing TNF-α and IL-1β production (Retracted article. See MAY, 2023)

A novel Er(III)-organic framework, {[Er-3(bPydb)(3)(HCOO)(OH)(H2O))]center dot 6H(2)O}(n) (1), was synthesized by hydrothermal reaction using a rigid tripodal nitrogen-containing heterotopic ligand 4,4'-(4,4'-bipyridine-2,6-diyl) dibenzoic acid (bpydbH(2)). In the biological experiments, the Cell Counting Kit-8 test was performed to detect the inhibitory effect of the compound on Caco-2 colon cancer cells. Then, RT-PCR was first utilized to study the compound's inhibitory function on the activation of the IL-6-STAT3 signaling pathway. In addition to this, expression level of STAT3 in the cancer cells, as well as the content of tIL-6 in the cell supernatant, was detected with western blotting assay. Next, ELISA detection was conducted to evaluate the content of IL-1 beta and TNE-alpha after compound treatment. The results of posture scoring and molecular docking software showed that the compound may bind to STAT-3, which may offer latent regulatory mechanisms as well as binding modes for compounds. [GRAPHICS] .